Syntaxin Limited
Abingdon, GB· latest recorded location
SYNTAXIN LIMITED is named on 36 US grants and 55 published applications in this corpus. Its most frequent classification is A61K (Medicines and medical preparations).
- Granted patents
- 36
- Published applications
- 55
- Inventors
- 34
- Granted in 2026 so far
- 0
- Most recent grant
- 22 Sep 2015
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 2 |
| 2006 | 0 | 1 |
| 2007 | 0 | 1 |
| 2008 | 3 | 4 |
| 2009 | 0 | 8 |
| 2010 | 4 | 3 |
| 2011 | 7 | 10 |
| 2012 | 4 | 10 |
| 2013 | 8 | 5 |
| 2014 | 4 | 7 |
| 2015 | 6 | 3 |
By publication year.
Technology areas
Share of 91 documents
- A61KMedicines and medical preparations88
- C07KPeptides88
- A61PTherapeutic uses of medicines85
- C12NMicroorganisms or enzymes78
- C12YEnzymes32
- Y02ATechnologies for adaptation to climate change20
- Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests17
- C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition3
- G01NInvestigating or analysing materials by determining their chemical or physical properties3
- A61QSpecific use of cosmetics or similar toiletry preparations1
Recent patents
- Non-cytotoxic protein conjugates22 Sep 2015US 9,139,635 B2
- Carrier for targeting nerve cells25 Aug 2015US 9,115,350 B2
- Treatment of pain7 Jul 2015US 9,072,736 B2
- Non-cytotoxic protein conjugates21 Apr 2015US 9,012,195 B2
- Fusion proteins17 Feb 2015US 8,956,847 B2
- Methods for the manufacture of proteolytically processed polypeptides13 Aug 2015US 2015/0225709 A1
- Carrier for targeting nerve cells5 Feb 2015US 2015/0038401 A1
- Transport protein which is used to introduce chemical compounds into nerve cells29 Jan 2015US 2015/0030584 A1
- Inhibition of secretion from non-neuronal cells27 Nov 2014US 2014/0348828 A1
- Suppression of neuroendocrine diseases9 Oct 2014US 2014/0302006 A1
Most cited
By later US patents